Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2003-7-28
pubmed:abstractText
We evaluated the renoprotective effects as reflected by short-term changes in albuminuria of dual blockade of the renin-angiotensin system (RAS) by adding an angiotensin II receptor blocker (ARB) to treatment with maximal recommended doses of an ACE inhibitor (ACEI) in patients with type 2 diabetes and nephropathy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0149-5992
pubmed:author
pubmed:issnType
Print
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2268-74
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:12882847-Aged, pubmed-meshheading:12882847-Angiotensin Receptor Antagonists, pubmed-meshheading:12882847-Angiotensin-Converting Enzyme Inhibitors, pubmed-meshheading:12882847-Antihypertensive Agents, pubmed-meshheading:12882847-Benzimidazoles, pubmed-meshheading:12882847-Captopril, pubmed-meshheading:12882847-Cross-Over Studies, pubmed-meshheading:12882847-Diabetes Mellitus, Type 2, pubmed-meshheading:12882847-Diabetic Nephropathies, pubmed-meshheading:12882847-Double-Blind Method, pubmed-meshheading:12882847-Drug Therapy, Combination, pubmed-meshheading:12882847-Enalapril, pubmed-meshheading:12882847-Female, pubmed-meshheading:12882847-Humans, pubmed-meshheading:12882847-Kidney, pubmed-meshheading:12882847-Lisinopril, pubmed-meshheading:12882847-Male, pubmed-meshheading:12882847-Middle Aged, pubmed-meshheading:12882847-Tetrazoles, pubmed-meshheading:12882847-Treatment Outcome
pubmed:year
2003
pubmed:articleTitle
Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
pubmed:affiliation
Steno Diabetes Center, Gentofte, Denmark. krossing@dadlnet.dk
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't